Querfeld U, Kohl B, Fiehn W, Minor T, Michalk D, Schärer K, Müller-Wiefel D E
University Children's Hospital, Cologne, Germany.
Pediatr Nephrol. 1999 Jan;13(1):7-12. doi: 10.1007/s004670050554.
In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome. Probucol was started for a total of 12 weeks in 8 children and for 24 weeks in 14 children. Lipoprotein profiles, serum malondialdehyde (MDA) levels, proteinuria, renal function, and electrocardiogram were monitored every 4 weeks. Side effects were recorded by questionnaire. Treatment was completed by 7 of 8 patients for 12 weeks and by 7 of 14 children for 24 weeks. After 12 weeks, the mean serum concentrations of triglycerides (-15%), total cholesterol (-25%), very low-density lipoprotein-cholesterol (-27%), low-density lipoprotein-cholesterol (-23%), and high-density lipoprotein-cholesterol (-24%), as well as apolipoprotein (apo) A-I (-19%), apo B (-21%), and MDA (-32%) were reduced. The positive effects of probucol on the lipoprotein profile persisted over 24 weeks; however, there was no significant effect on either proteinuria or GFR. In conclusion, probucol had beneficial effects on lipoproteins and lipid peroxidation, but improved neither proteinuria nor GFR. The drug was generally tolerated well, but had to be discontinued because of a prolonged QT interval in 4 of 22 patients.
在一项前瞻性、非对照多中心研究中，我们评估了普罗布考对持续性肾病综合征高脂血症儿童的高脂血症、蛋白尿和肾小球滤过率（GFR）的影响。8名儿童服用普罗布考共12周，14名儿童服用24周。每4周监测一次脂蛋白谱、血清丙二醛（MDA）水平、蛋白尿、肾功能和心电图。通过问卷调查记录副作用。8名患者中有7名完成了12周的治疗，14名儿童中有7名完成了24周的治疗。12周后，甘油三酯（-15%）、总胆固醇（-25%）、极低密度脂蛋白胆固醇（-27%）、低密度脂蛋白胆固醇（-23%）和高密度脂蛋白胆固醇（-24%）的平均血清浓度，以及载脂蛋白（apo）A-I（-19%）、apo B（-21%）和MDA（-32%）均降低。普罗布考对脂蛋白谱的积极作用持续24周；然而，对蛋白尿或GFR均无显著影响。总之，普罗布考对脂蛋白和脂质过氧化有有益作用，但对蛋白尿和GFR均无改善。该药物总体耐受性良好，但22名患者中有4名因QT间期延长而不得不停药。
